Phases, active trials: Phase 1: 47, Phase 2: 42, Phase 3: 78, Other: 39
Following the separation of the consumer business, Johnson & Johnson's pharmaceutical arm (Janssen) operates one of the strongest oncology and immunology pipelines in the industry. In hematology, Darzalex (daratumumab) for multiple myeloma continues expanding into earlier lines and new combinations, while Carvykti (ciltacabtagene autoleucel), the BCMA CAR-T therapy, advances into earlier myeloma settings. Rybrevant (amivantamab), the EGFR-MET bispecific antibody for NSCLC, is rapidly expanding with combination programs including lazertinib. In prostate cancer, Erleada (apalutamide) and Akeega (niraparib/abiraterone) address different molecular subgroups. Their immunology pipeline spans Stelara (ustekinumab), Tremfya (guselkumab), and a next-generation IL-23/IL-17 portfolio.
- Hematology (multiple myeloma, CAR-T)
- Thoracic oncology (EGFR-MET bispecific)
- Prostate cancer
- Immunology / dermatology (IL-23, IL-17)
- Solid tumor immuno-oncology
- Darzalex (daratumumab): CD38, multiple myeloma
- Carvykti (ciltacabtagene autoleucel): BCMA CAR-T
- Rybrevant (amivantamab): EGFR-MET bispecific, NSCLC
- Erleada (apalutamide): non-metastatic/metastatic CRPC
- Akeega (niraparib + abiraterone): HRR-mutated prostate
- Tremfya (guselkumab): IL-23p19, psoriasis/IBD
A primary completion date pushed out, enrollment cut, or a primary endpoint changed in the last 90 days. Active trials only.
| Trial | Warning signs | Status |
|---|---|---|
| A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With… NCT05265273 | Primary completion moved at least 12 months later | Recruiting |
16 more on the Trials at Risk page. See which trials →
Phase 2 and Phase 3 trials with a primary completion date in the next 180 days, as ClinicalTrials.gov estimates it today. Active trials only.
| Trial | Scheduled | Phase |
|---|---|---|
| A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in… NCT05884398 | Oct 12, 2026 · Estimated | Phase 3 |
14 more on the Completions page. See the calendar →
Monitor the Johnson & Johnson / Janssen pipeline daily
Get a daily digest when Johnson & Johnson / Janssen registers new trials or updates existing protocols. Free plan, no credit card required.
Start monitoring free| Condition / indication | Active trials |
|---|---|
| Multiple Myeloma | 25 |
| Colitis, Ulcerative | 17 |
| Carcinoma, Non-Small-Cell Lung | 13 |
| Crohn Disease | 13 |
| Prostatic Neoplasms | 13 |
| Arthritis, Psoriatic | 12 |
| Crohn's Disease | 7 |
| Lymphoma, Non-Hodgkin | 7 |
J&J's Rybrevant + lazertinib combination represents the most significant competitive threat to Tagrisso (osimertinib) in EGFR-mutant NSCLC. Any company active in lung cancer or multiple myeloma must monitor Janssen's Phase 3 pipeline in those indications.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Johnson & Johnson / Janssen's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.
- Sponsor normalization: Johnson & Johnson / Janssen may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your Johnson & Johnson / Janssen pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Get started free| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib… NCT07665450 | Recruiting | Trial sites expanded: 19 → 30 locations | 2026-10-07 |
| A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine… NCT07589634 | Recruiting | Trial sites expanded: 9 → 38 locations | 2026-10-02 |
| A Long-term Extension Study of PCI-32765 (Ibrutinib) NCT01804686 | Active, Not Recruiting | Final enrollment: 539 participants (planned 700) | 2026-10-02 |
| A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With… NCT07573176 | Recruiting | Trial sites expanded: 39 → 45 locations | 2026-10-02 |
| Evaluation of Approved Contact Lenses (CR-6657) NCT07819305 | Recruiting | Recruitment opened | 2026-09-30 |
Each trial page shows every change DataLookout has recorded for that trial.